Medical Advocates
Etravirine (Intelence/TMC125)
  Conference Citations Archives B
 16th Int HIV Drug Resistance Workshop
IDSA -2007
 47th Annual ICAAC
4th IAS Conference
 5th European HIV Drug Resistance Conference
11th European AIDS Conference
14th CROI
 American Conference on HIV Treatment-2007
 8th Int Congress on Drug Therapy in HIV Infection
XVI International AIDS Conference
IDSA 2006
46th Annual ICAAC
 15th International Drug Resistance Workshop
 Conference Archives – C		  
Etravirine Main Page Conferences Main Page Home Page      
Last Update:  April 25, 2009 
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
16th International HIV Drug Resistance Workshop
 
IDSA 2007
 
47th Annual ICAAC
 

4th IAS Conference
 
  • DUET-1: 24 week results of a phase III randomised double-blind trial to evaluate the efficacy
    and safety of TMC125 versus placebo in 612 treatment-experienced HIV-1 infected patients
         Mills A, Cahn P, Grinsztejn B, et al
         Abstract
  • DUET-2: 24 week results of a phase III randomised double-blind trial to evaluate the efficacy
    and safety of TMC125 versus placebo in 591 treatment-experienced HIV-1 infected patients
         Katlama C, Campbell T, Clotet B, et al
         Abstract
  • POSTER
         Pharmacokinetic interaction between the non-nucleoside reverse transcriptase inhibitor
    (NNRTI) TMC125 and atorvastatin in HIV-negative volunteers
         Schöller-Gyüre M, Kakuda TN, De Smedt G, et al
         PDF Poster  Abstract
  • HIV-1 NNRTI mutation profiles in clinical practice: implications for TMC125 use
         Cotte L, Trabaud M-A, Tardy J-C, et al
         Abstract
  • POSTER
         Pharmacokinetic evaluation of non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC125
    and integrase inhibitor (InSTI) raltegravir (RAL) in healthy subjects
         Anderson MS., Kakuda TN., Miller JL., et al
         PDF Poster   Abstract
5th European HIV Drug Resistance Workshop
 
8th Int Congress on Drug Therapy in HIV Infection
 
  • POSTER
     No effect of TMC125 on the pharmacokinetics of oral contraceptives
         M Schöller-Gyüre, C Debroye, F Aharchi, et al
    PDF Poster  Abstract
  • POSTER
         No frequent reporting of neurological or psychiatric events during TMC125 treatment
    B Woodfall, G De Smedt, C Berckmans, et al
    PDF Poster  Abstract
  • Impact of NNRTI and NRTI resistance on the response to the regimen of TMC125 plus two NRTIs
    in Study TMC125-C227
         B Woodfall, J Vingerhoets, M Peeters, et al
         Abstract
  • POSTER
    Pharmacokinetics of TMC125, with atazanavir (ATV) and atazanavir/ritonavir (ATV/r)
     Schöller-Gyüre, B Woodfall, T De Marez, et al
         PDF Poster  Abstract
14th Conference on Retroviruses and Opportunistic
Infections
The American Conference for the Treatment of HIV- 2007
 
8th Int Congress on Drug Therapy in HIV Infection
 
  • POSTER
         No effect of TMC125 on the pharmacokinetics of oral contraceptives
         M Schöller-Gyüre, C Debroye, F Aharchi, et al
    PDF Poster      Abstract
  • POSTER
         No frequent reporting of neurological or psychiatric events during TMC125 treatment
    B Woodfall, G De Smedt, C Berckmans, et al
    PDF Poster      Abstract
  • Impact of NNRTI and NRTI resistance on the response to the regimen of TMC125 plus two NRTIs
    in Study TMC125-C227
         B Woodfall, J Vingerhoets, M Peeters, et al
         Abstract
  • POSTER
    Pharmacokinetics of TMC125, with atazanavir (ATV) and atazanavir/ritonavir (ATV/r)
         Schöller-Gyüre, B Woodfall, T De Marez, et al
         PDF Poster  Abstract
XVI International AIDS Conference
     
  • TMC125 bioavailability is not affected by ranitidine and omeprazole
     M. Schöller-Gyüre, G. De Smedt, H. Vanaken, et al
         Abstract
  • Combination of TMC114/ritonavir and TMC125 in patients with multidrug resistant HIV
    Montaner J., Harris M., Larsen G., et al
     Abstract
  • Pharmacokinetic interaction study with TMC125 and TMC114/rtv in HIV-negative volunteers
    Kakuda T., Schöller-Gyüre M., Peeters M., et al
     Abstract
  • Lack of interaction between TMC125 and methadone
    Schöller-Gyüre M., Woodfall B., Vanaken H., et al
     Abstract
  • Prediction of clinical benefits of TMC125 from treatment effects on CD4 counts and HIV RNA
    Grossman H., Cohen C., Nadler J., et al
     Abstract
  • Efficacy and safety results at 48 weeks with the novel NNRTI, TMC125, and impact of baseline
    resistance on the virologic response in study TMC125-C223
    Cohen C., Steinhart C., Ward D., et al
     Abstract
IDSA 2006
 
46th Annual ICAAC
 
15th International Drug Resistance Workshop
     

Etravirine Main Page Conferences Main Page Home Page      

Etravirine Conference Citations Archives B